Metraipolis › archive › dc_138a0aa294ca

Cost-effectiveness analysis of sacituzumab tirumotecan vs. chemotherapy for patients with EGFR-TKI-resistant, EGFR-mutated advanced non-small cell lung cancer… — Europe PMC PMID:42577174

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42577174
DOI
10.3389/fpubh.2026.1843636
License (as archived)
solo-consultazione
Archived
2026-10-17T16:21:11.492Z
SHA-256 of the archived text
1ac208ece979739e69e0f55cf3d5d85e85099222fd37e4bea6ef56cf11c8c34f
Stable URL of this page
https://metraipolis.com/documento/dc_138a0aa294ca

How to cite

Cost-effectiveness analysis of sacituzumab tirumotecan vs. chemotherapy for patients with EGFR-TKI-resistant, EGFR-mutated advanced non-small cell lung cancer… — Europe PMC PMID:42577174 — Europe PMC (en), https://europepmc.org/article/MED/42577174 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_138a0aa294ca (Metraipolis archive dc_138a0aa294ca, sha256 1ac208ece979739e69e0f55cf3d5d85e85099222fd37e4bea6ef56cf11c8c34f)
BibTeX
@misc{dc138a0aa294ca,
  title = {Cost-effectiveness analysis of sacituzumab tirumotecan vs. chemotherapy for patients with EGFR-TKI-resistant, EGFR-mutated advanced non-small cell lung cancer… — Europe PMC PMID:42577174},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42577174},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_138a0aa294ca; sha256 1ac208ece979739e69e0f55cf3d5d85e85099222fd37e4bea6ef56cf11c8c34f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42577174. Agents can read the archived copy with the MCP tool read_document.